Glabellar Botulinum Toxin Injections in Major Depressive Disorder: A Critical Review

Toren P. Stearns, Mujeeb Shad, Gabriela C. Guzman

    Research output: Contribution to journalArticle

    1 Citation (Scopus)

    Abstract

    Data Sources: A search in PubMed, Scopus, and Google Scholar databases was performed in September 2017. Search terms included ("botulinum" OR "botox" OR "abobotulinumtoxin" OR "onabotulinum" OR "onabotulinumtoxin" OR "botulinumtoxin") AND ("antidepressant" OR "depression" OR "depressive" OR "depressed"). No other search parameters were utilized.

    Study Selection: Studies were selected for review if they were found to be a primary clinical trial on the use of BTA for the treatment of MDD.

    Data Extraction: Six studies were identified and scored by the authors using a 5-point Jadad scoring system.

    Results: Three of the 6 studies were found to be of high quality with a Jadad score ≥ 3. The remainder had Jadad scores of 1.

    Conclusions: In general, the results from the reviewed studies suggest that BTA may be a promising treatment for MDD. However, these findings need to be interpreted with caution due to several limitations of the reviewed studies such as lack of a priori hypotheses, limited sample sizes, large gender bias, and significant difficulty in ensuring blinding.

    Objective: To provide a critical appraisal of the primary clinical trials exploring the use of glabellar botulinum toxin type A (BTA) injections in the treatment of major depressive disorder (MDD) and propose future directions for research on this topic.

    Original languageEnglish (US)
    JournalThe primary care companion for CNS disorders
    Volume20
    Issue number5
    DOIs
    StatePublished - Oct 4 2018

    Fingerprint

    Type A Botulinum Toxins
    Botulinum Toxins
    Major Depressive Disorder
    Injections
    Clinical Trials
    Sexism
    Information Storage and Retrieval
    PubMed
    Sample Size
    Antidepressive Agents
    Therapeutics
    Databases
    Depression
    Research

    ASJC Scopus subject areas

    • Medicine(all)

    Cite this

    Glabellar Botulinum Toxin Injections in Major Depressive Disorder : A Critical Review. / Stearns, Toren P.; Shad, Mujeeb; Guzman, Gabriela C.

    In: The primary care companion for CNS disorders, Vol. 20, No. 5, 04.10.2018.

    Research output: Contribution to journalArticle

    @article{c3eb65eb32334fc3b502a2d16e58a1fa,
    title = "Glabellar Botulinum Toxin Injections in Major Depressive Disorder: A Critical Review",
    abstract = "Data Sources: A search in PubMed, Scopus, and Google Scholar databases was performed in September 2017. Search terms included ({"}botulinum{"} OR {"}botox{"} OR {"}abobotulinumtoxin{"} OR {"}onabotulinum{"} OR {"}onabotulinumtoxin{"} OR {"}botulinumtoxin{"}) AND ({"}antidepressant{"} OR {"}depression{"} OR {"}depressive{"} OR {"}depressed{"}). No other search parameters were utilized.Study Selection: Studies were selected for review if they were found to be a primary clinical trial on the use of BTA for the treatment of MDD.Data Extraction: Six studies were identified and scored by the authors using a 5-point Jadad scoring system.Results: Three of the 6 studies were found to be of high quality with a Jadad score ≥ 3. The remainder had Jadad scores of 1.Conclusions: In general, the results from the reviewed studies suggest that BTA may be a promising treatment for MDD. However, these findings need to be interpreted with caution due to several limitations of the reviewed studies such as lack of a priori hypotheses, limited sample sizes, large gender bias, and significant difficulty in ensuring blinding.Objective: To provide a critical appraisal of the primary clinical trials exploring the use of glabellar botulinum toxin type A (BTA) injections in the treatment of major depressive disorder (MDD) and propose future directions for research on this topic.",
    author = "Stearns, {Toren P.} and Mujeeb Shad and Guzman, {Gabriela C.}",
    year = "2018",
    month = "10",
    day = "4",
    doi = "10.4088/PCC.18r02298",
    language = "English (US)",
    volume = "20",
    journal = "The primary care companion for CNS disorders",
    issn = "1523-5998",
    publisher = "Physicians Postgraduate Press Inc.",
    number = "5",

    }

    TY - JOUR

    T1 - Glabellar Botulinum Toxin Injections in Major Depressive Disorder

    T2 - A Critical Review

    AU - Stearns, Toren P.

    AU - Shad, Mujeeb

    AU - Guzman, Gabriela C.

    PY - 2018/10/4

    Y1 - 2018/10/4

    N2 - Data Sources: A search in PubMed, Scopus, and Google Scholar databases was performed in September 2017. Search terms included ("botulinum" OR "botox" OR "abobotulinumtoxin" OR "onabotulinum" OR "onabotulinumtoxin" OR "botulinumtoxin") AND ("antidepressant" OR "depression" OR "depressive" OR "depressed"). No other search parameters were utilized.Study Selection: Studies were selected for review if they were found to be a primary clinical trial on the use of BTA for the treatment of MDD.Data Extraction: Six studies were identified and scored by the authors using a 5-point Jadad scoring system.Results: Three of the 6 studies were found to be of high quality with a Jadad score ≥ 3. The remainder had Jadad scores of 1.Conclusions: In general, the results from the reviewed studies suggest that BTA may be a promising treatment for MDD. However, these findings need to be interpreted with caution due to several limitations of the reviewed studies such as lack of a priori hypotheses, limited sample sizes, large gender bias, and significant difficulty in ensuring blinding.Objective: To provide a critical appraisal of the primary clinical trials exploring the use of glabellar botulinum toxin type A (BTA) injections in the treatment of major depressive disorder (MDD) and propose future directions for research on this topic.

    AB - Data Sources: A search in PubMed, Scopus, and Google Scholar databases was performed in September 2017. Search terms included ("botulinum" OR "botox" OR "abobotulinumtoxin" OR "onabotulinum" OR "onabotulinumtoxin" OR "botulinumtoxin") AND ("antidepressant" OR "depression" OR "depressive" OR "depressed"). No other search parameters were utilized.Study Selection: Studies were selected for review if they were found to be a primary clinical trial on the use of BTA for the treatment of MDD.Data Extraction: Six studies were identified and scored by the authors using a 5-point Jadad scoring system.Results: Three of the 6 studies were found to be of high quality with a Jadad score ≥ 3. The remainder had Jadad scores of 1.Conclusions: In general, the results from the reviewed studies suggest that BTA may be a promising treatment for MDD. However, these findings need to be interpreted with caution due to several limitations of the reviewed studies such as lack of a priori hypotheses, limited sample sizes, large gender bias, and significant difficulty in ensuring blinding.Objective: To provide a critical appraisal of the primary clinical trials exploring the use of glabellar botulinum toxin type A (BTA) injections in the treatment of major depressive disorder (MDD) and propose future directions for research on this topic.

    UR - http://www.scopus.com/inward/record.url?scp=85055079839&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=85055079839&partnerID=8YFLogxK

    U2 - 10.4088/PCC.18r02298

    DO - 10.4088/PCC.18r02298

    M3 - Article

    C2 - 30326186

    AN - SCOPUS:85055079839

    VL - 20

    JO - The primary care companion for CNS disorders

    JF - The primary care companion for CNS disorders

    SN - 1523-5998

    IS - 5

    ER -